Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?

The continuous glucose monitoring system (CGM) has been used for constant checking of glucose level by measuring interstitial glucose concentrations, since the early days of the 21st century. It can potentially improve diabetes care if used carefully with the understanding of the characteristics of...

Full description

Bibliographic Details
Main Authors:	Sato, Junko, Hirose, Takahisa, Watada, Hirotaka
Format:	Online
Language:	English
Published:	Blackwell Publishing Ltd 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014941/

id	pubmed-4014941
recordtype	oai_dc
spelling	pubmed-40149412014-05-19 Continuous glucose monitoring system: Is it really accurate, safe and clinically useful? Sato, Junko Hirose, Takahisa Watada, Hirotaka Review Articles The continuous glucose monitoring system (CGM) has been used for constant checking of glucose level by measuring interstitial glucose concentrations, since the early days of the 21st century. It can potentially improve diabetes care if used carefully with the understanding of the characteristics of this system. Although there is a time lag of approximately 5–15 min between blood and interstitial glucose levels, the system is considered the most suitable device for meticulous glucose control and prevention of hypoglycemia. A large number of studies have examined its accuracy, safety and clinical effectiveness. The continuous glucose‐error grid analysis (CG‐EGA), designed by WL Clarke, evaluates the clinical accuracy of CGM. It examines ‘temporal’ characteristics of the data, analyzing pairs of reference and sensor readings as a process in time represented by a ‘bidimensional’ time series and taking into account inherent physiological time lags. Investment in CG‐EGA is clearly meaningful, even though there are other methodologies for evaluation. The use of each method complementarily is the most effective way to prove the accuracy of the device. The device has improved gradually, and real‐time CGM, which allows real‐time monitoring of blood glucose level, is already available commercially. The use of real‐time CGM could potentially lead to over‐ or undertreatment with insulin. Patient education through proper and effective handling of the new device is essential to improve diabetes care. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00197.x, 2012) Blackwell Publishing Ltd 2012-06-06 2012-02-17 /pmc/articles/PMC4014941/ /pubmed/24843568 http://dx.doi.org/10.1111/j.2040-1124.2012.00197.x Text en © 2012 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Sato, Junko Hirose, Takahisa Watada, Hirotaka
spellingShingle	Sato, Junko Hirose, Takahisa Watada, Hirotaka Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?
author_facet	Sato, Junko Hirose, Takahisa Watada, Hirotaka
author_sort	Sato, Junko
title	Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?
title_short	Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?
title_full	Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?
title_fullStr	Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?
title_full_unstemmed	Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?
title_sort	continuous glucose monitoring system: is it really accurate, safe and clinically useful?
description	The continuous glucose monitoring system (CGM) has been used for constant checking of glucose level by measuring interstitial glucose concentrations, since the early days of the 21st century. It can potentially improve diabetes care if used carefully with the understanding of the characteristics of this system. Although there is a time lag of approximately 5–15 min between blood and interstitial glucose levels, the system is considered the most suitable device for meticulous glucose control and prevention of hypoglycemia. A large number of studies have examined its accuracy, safety and clinical effectiveness. The continuous glucose‐error grid analysis (CG‐EGA), designed by WL Clarke, evaluates the clinical accuracy of CGM. It examines ‘temporal’ characteristics of the data, analyzing pairs of reference and sensor readings as a process in time represented by a ‘bidimensional’ time series and taking into account inherent physiological time lags. Investment in CG‐EGA is clearly meaningful, even though there are other methodologies for evaluation. The use of each method complementarily is the most effective way to prove the accuracy of the device. The device has improved gradually, and real‐time CGM, which allows real‐time monitoring of blood glucose level, is already available commercially. The use of real‐time CGM could potentially lead to over‐ or undertreatment with insulin. Patient education through proper and effective handling of the new device is essential to improve diabetes care. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2012.00197.x, 2012)
publisher	Blackwell Publishing Ltd
publishDate	2012
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014941/
_version_	1612086945690681344

Continuous glucose monitoring system: Is it really accurate, safe and clinically useful?

Similar Items